Optimizing Treatment of Follicular Lymphoma : Episode 8

Treatment Options After Second-Line Relapse

Jan 28, 2020

Transcript:

FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169 in Multiple Myeloma, Hodgkin Lymphoma

June 8th 2023

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

June 6th 2023

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

June 2nd 2023

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169 in Multiple Myeloma, Hodgkin Lymphoma

June 8th 2023

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

June 6th 2023

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

June 2nd 2023

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169 in Multiple Myeloma, Hodgkin Lymphoma

June 8th 2023

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

June 6th 2023

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

June 2nd 2023

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

Related Content

MT-0169 in Multiple Myeloma, Hodgkin Lymphoma | Image Credit: ©immimagery - stock.adobe.com

FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169 in Multiple Myeloma, Hodgkin Lymphoma

June 8th 2023

Article

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

Podcast

$Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.$

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

June 6th 2023

Article

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

Podcast

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

June 2nd 2023

Article

$Obecatagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.$